ASHVATTHA THERAPEUTICS

Aviceda

This biotechnology company develops nanoparticle glyco-therapeutics for patients with immune-mediated diseases, primarily targeting macular degeneration and other ophthalmic, neurological and inflammatory conditions.

Aviceda Therapeutics

This biotechnology firm develops glycan-coated nanoparticle therapeutics to treat geographic atrophy and other inflammatory diseases for patients with vision loss.

Iveric Bio

This biopharmaceutical company develops therapeutic treatments for retinal diseases and provides these medicines to patients with age-related macular degeneration and inherited conditions.

Adverum Biotechnologies

The company develops ocular gene therapies to treat retinal diseases for patients with vision-threatening conditions such as wet age-related macular degeneration.

PulseSight Therapeutics

This company develops non-viral gene therapies for patients with severe eye diseases including age-related macular degeneration.

AsclepiX Therapeutics

This biopharmaceutical firm develops peptide therapeutics for patients with retinal diseases and cancer using a computational biology platform.

ADARx Pharmaceuticals

This clinical-stage biotechnology company develops RNA-targeting therapeutics for patients with genetic, cardiometabolic, complement-mediated, and central nervous system diseases.

Atsena Therapeutics

This clinical-stage company develops gene therapies to treat and prevent inherited retinal diseases for patients with conditions such as X-linked retinoschisis and Stargardt disease.